• Francisco Tejada Cifuentes, Ángeles Lloret Callejo, María José Tirado Peláez, Olga Rubio Pulido, Marta Ruiz-Morote Aragón, Rocío Fernández Urrusuno, María Isabel Muñoz Carreras, María Isabel Méndez Esteban, Victoria Maestre Sánchez, Antonio García Bonilla, José Manuel Paredero Dominguez, Virginia Arroyo Pineda, Esther Marco Tejón, Gregorio Romero Candel, Ana Isabel Fernández Marchante, José Marco Del Rio, Teresa Ortiz Martín, and Piedad López Sánchez.
• Gerencia de Atención Integrada de Albacete, Albacete, España. Electronic address: ftejada@sescam.jccm.es.
• Med Clin (Barc). 2021 Feb 26; 156 (4): 166-171.

ObjectiveTo analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine.Patients And MethodsCross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded.Results169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P<.05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (P<.05).ConclusionThere is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

39 keywords...

hide…